Update on botulinum toxin and dermal fillers

Current Opinion in Ophthalmology

Volumn 21, Issue 5, 2010, Pages 387-395

  Berbos, Zachary J ^a   Lipham, William J ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MINNESOTA EYE CONSULTANTS   (United States)

Author keywords

botulinum toxin; dermal fillers; facial rejuvenation

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; HYALURONIC ACID; HYDROXYAPATITE; LIDOCAINE; POLY(METHYL METHACRYLATE); SILICONE; MUSCLE RELAXANT AGENT; VISCOELASTIC SUBSTANCE;

CERVICAL DYSTONIA; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DYSTONIC DISORDER; FACIAL REJUVENATION; FACIES; HUMAN; INJECTION SITE; NON INVASIVE PROCEDURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TISSUE NECROSIS; CHEMISTRY; CUTANEOUS PARAMETERS; ESTHETIC SURGERY; PROCEDURES; REJUVENATION; RHYTIDOPLASTY;

BOTULINUM TOXIN TYPE A; COSMETIC TECHNIQUES; HUMANS; NEUROMUSCULAR AGENTS; REJUVENATION; RHYTIDOPLASTY; SKIN AGING; VISCOELASTIC SUBSTANCES; BOTULINUM TOXINS, TYPE A;

EID: 77955921780     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32833ce7bc     Document Type: Review

References (70)

1. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87:1044-1049.
2. Charles PD. Botulinum neurotoxin serotype A: a clinical update on noncosmetic uses. Am J Health Syst Pharm 2004; 61 (22 Suppl 6):S11-S23.
3. Zalvan C, Bentsianov B, Gonzalez-Yanes O, Blitzer A. Noncosmetic uses of botulinum toxin. Dermatol Clin 2004; 22:187-195. (Pubitemid 38638572)
4. Aoki KR. Pharmacology and immunology of botulinum neurotoxins. Int Ophthalmol Clin 2005; 45:25-37.
5. Melling J, Hambleton P, Shone CC. Clostridium botulinum toxins: nature and preparation for clinical use. Eye (Lond) 1988; 2 (Pt 1):16-23.
6. Hankins CL, Strimling R, Rogers GS. Botulinum A toxin for glabellar wrinkles. Dose and response. Dermatol Surg 1998; 24:1181-1183.
7. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001; 8 (Suppl 5):21-29.
8. Foran PG, Mohammed N, Lisk GO, et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 2003; 278:1363-1371.
9. Badarny S, Susel Z, Honigman S. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox. Isr Med Assoc J 2008; 10:520-522.
10. Hexsel DM, De Almeida AT, Rutowitsch M, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg 2003; 29:523-529; discussion 529.
11. Hui JI, Lee WW. Efficacy of fresh versus refrigerated botulinum toxin in the treatment of lateral periorbital rhytids. Ophthal Plast Reconstr Surg 2007; 23:433-438.
12. Yang GC, Chiu RJ, Gillman GS. Questioning the need to use Botox within 4 h of reconstitution: a study of fresh vs 2-week-old Botox. Arch Facial Plast Surg 2008; 10:273-279.
13. Jabor MA, Kaushik R, Shayani P, et al. Efficacy of reconstituted and stored botulinum toxin type A: an electrophysiologic and visual study in the auricular muscle of the rabbit. Plast Reconstr Surg 2003; 111:2419-2426; discussion 2427-2431.
14. Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Ophthalmol 2007; 52:13-31.
15. Alam M, Yoo SS, Wrone DA, et al. Sterility assessment of multiple use botulinum A exotoxin vials: a prospective simulation. J Am Acad Dermatol 2006; 55:272-275.
16. Kane MA, Brandt F, Rohrich RJ, et al. Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, doubleblind, placebo-controlled study. Plast Reconstr Surg 2009; 124:1619-1629.
17. Hexsel D, Rutowitsch MS, de Castro LCM, et al. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection. Dermatol Surg 2009; 35:933-939; discussion 940.
18. Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg 2009; 35:1-8.
19. Kranz G, Haubenberger D, Voller B, et al. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord 2009; 24:231-236.
20. Krack P, Deuschl G, Benecke R, et al. Dose standardization of botulinum toxin. Mov Disord 1998; 13:749-751.
21. Wohlfarth K, Schwandt I, Wegner F, et al. Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol 2008; 255:1932-1939.
22. Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001; 39:1815-1820.
23. Lowe PL, Patnaik R, Lowe NJ. A comparison of two botulinum type A toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study. Dermatol Surg 2005; 31:1651-1654.
24. Trindade de Almeida AR, Marques E, de Almeida J, et al. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33 (1 Spec No.):S37-S43.
25. Cliff SH, Judodihardjo H, Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol 2008; 7:50-54.
26. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers' product summaries. J Clin Pharm Ther 2007; 32:387-402.
27. Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, doubleblind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51:223-233.
28. Ascher B, Zakine B, Kestemont P, et al. Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthet Surg J 2005; 25:365-375.
29. Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol 2006; 55:975-980.
30. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 2007; 33(1 Spec No.):S51-S59. (Pubitemid 46051400)
31. Frevert J. Xeomin: an innovative new botulinum toxin type A. Eur J Neurol 2009; 16 (Suppl 2):11-13.
32. Carruthers A, Carruthers J. Botulinum toxin products overview. Skin Therapy Lett 2008; 13:1-4.
33. Roggenkämper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006; 113:303-312.
34. Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 2007; 67:669-683. (Pubitemid 46535642)
35. Frevert J. Xeomin is free from complexing proteins. Toxicon 2009; 54:697-701.
36. Carruthers A, Carruthers J, Cohen J. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter? Dermatol Surg 2007; 33 (1 Spec No.):S97-104.
37. Hsu TSJ, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004; 140:1351-1354.
38. Carruthers A, Carruthers J. Prospective double-blind, randomized, parallelgroup, doseranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 2005; 31:1297-1303.
39. Callaway J. Botulinum toxin type B (Myobloc): pharmacology and biochemistry [review]. Clin Dermatol 2004; 22:23-28.
40. Sadick N, Herman A. Comparison of botulinum toxins A and B in the aesthetic treatment of facial rhytides [review]. Dermatol Surg 2003; 29: 340-347.
41. Setler P. The biochemistry of botulinum toxin type B. Neurology 2000; 55(Suppl 5):S22-S28.
42. Matarasso S. Complications of botulinum A exotoxin for hyperfunctional lines [review]. Dermatol Surg 1998; 24:1249-1254.
43. Spencer JM, Gordon M, Goldberg DJ. Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis. J Cosmet Laser Ther 2002; 4:19-23.
44. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure [republished in J Neurol 2003; 250:1263-1265]. J Neurol 2003; 250:967-969. (Pubitemid 37041029)
45. Klein AW. Techniques for soft tissue augmentation: an 'a to z'. Am J Clin Dermatol 2006; 7:107-120.
46. Beasley KL, Weiss MA, Weiss RA. Hyaluronic acid fillers: a comprehensive review. Facial Plast Surg 2009; 25:86-94.
47. Lupo M. Hyaluronic acid fillers in facial rejuvenation [review]. Semin Cutan Med Surg 2006; 25:122-126.
48. Monheit G, Coleman K. Hyaluronic acid fillers [review]. Dermatol Ther 2006; 19:141-150.
49. Narins R, Bowman P. Injectable skin fillers [review]. Clin Plast Surg 2005; 32:151-162.
50. De Boulle K. Management of complications after implantation of fillers. J Cosmet Dermatol 2004; 3:2-15.
51. Carruthers J, Glogau R, Blitzer A, Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies: consensus recommendations. Plast Reconstr Surg 2008; 121(Suppl 5):5S-30S.
52. Weiss R, Lavin P. Reduction of pain and anxiety prior to botulinum toxin injections with a new topical anesthetic method. Ophthal Plast Reconstr Surg 2009; 25:173-177.
53. Weinkle S, Bank D, Boyd C, et al. A multicenter, double-blind, randomized controlled study of the safety and effectiveness of Juvéderm injectable gel with and without lidocaine. J Cosmet Dermatol 2009; 8:205-210.
54. Wesley N, Dover J. The filler revolution: a six-year retrospective. J Drugs Dermatol 2009; 8:903-907.
55. Monheit GD, Campbell RM, Neugent H, et al. Reduced pain with use of proprietary hyaluronic acid with lidocaine for correction of nasolabial folds: a patient-blinded, prospective, randomized controlled trial. Dermatol Surg 2010; 36:94-101.
56. Cohen JL. Understanding, avoiding, and managing dermal filler complications. Dermatol Surg 2008; 34 (Suppl 1):S92-S99.
57. Brody HJ. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement. Dermatol Surg 2005; 31 (8 Pt 1):893-897.
58. Born T. Hyaluronic acids. Clin Plast Surg 2006; 33:525-538.
59. Carruthers J, Carruthers A. Complications of botulinum toxin type A [review]. Facial Plast Surg Clin North Am 2007; 15:51-54. (Pubitemid 46296571)
60. Schanz S, Schippert W, Ulmer A, et al. Arterial embolization caused by injection of hyaluronic acid (Restylane). J Dermatol 2002; 146:928-929.
61. Donath A, Glasgold R,Glasgold M. Volume loss versus gravity: new concepts in facial aging [review]. Curr Opin Otolaryngol Head Neck Surg 2007; 15:238-243.
62. Coleman K, Carruthers J. Combination therapy with BOTOX and fillers: the new rejuvenation paradigm [review]. Dermatol Ther 2006; 19:177-188.
63. Carruthers J, Carruthers A, Maberley D. Deep resting glabellar rhytides respond to BTX-A and Hylan B. Dermatol Surg 2003; 29:539-544.
64. Patel M, Talmor M, Nolan W. Botox and collagen for glabellar furrows: advantages of combination therapy. Ann Plast Surg 2004; 52:442-447.
65. Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 2003; 29:802-809.
66. Mendelson B, Hartley W, Scott M, et al. Age-related changes of the orbit and midcheek and the implications for facial rejuvenation. Aesthetic Plast Surg 2007; 31:419-423.
67. Tan SR, Glogau RG. Filler esthetics. In: Carruthers A, Carruthers J (eds). Procedures in cosmetic dermatology series: soft tissue augmentation. Philadelphia, PA, USA: Saunders; 2005.
68. Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. Facial Plast Surg 2002; 18:35-39.
69. Gassner HG, Brissett AE, Otley CC, et al. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc 2006; 81:1023-1028.
70. Wilson AM. Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg 2006; 117:1758-1766; discussion 1767-1768.